

Application No.
Reply to Office Action of10/595,807 Amendment Dated
December 31, 2008

June 1, 2009


JUN 01 2009

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A compound of formula (I):



wherein:

A is a direct bond or C_{1-2} alkylene; wherein said C_{1-2} alkylene may be optionally substituted by one or more R^{22} ;

Ring C is carbocyclyl or heterocyclyl;

R^1 and R^4 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R^1 and R^4 independently of each other may be optionally substituted on carbon by one or more R^8 ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^9 ;

R^2 is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl) $_2$ amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl) $_2$ carbamoyl, C_{1-6} alkylS(O) $_a$ wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl) $_2$ sulphamoyl,

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

R³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl, N,N-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R³ may be optionally substituted on carbon by one or more R¹²; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹³;

R⁶ is hydrogen or optionally substituted C₁₋₆alkyl; wherein said optional substituents are selected from one or more R¹⁴;

R⁸ and R⁷ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl, N,N-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁶ and R⁷ independently of each other may be optionally substituted on carbon by one or more R¹⁵; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁶;

~~or R⁶ and R⁷ together with the pyrimidine bond to which they are attached form a 5 or 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R¹⁷; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁸;~~

n = 0, 1, 2 or 3; wherein the values of R³ may be the same or different;

R⁸, R¹⁰, R¹², R¹⁴, R¹⁵, R¹⁷ and R²² are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl,

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl, N,N-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R⁸, R¹⁰, R¹², R¹⁴, R¹⁶, R¹⁷ and R²² independently of each other may be optionally substituted on carbon by one or more R¹⁸; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ are independently selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl; wherein R⁹, R¹¹, R¹³, R¹⁶, R¹⁸ and R²⁰ independently of each other may be optionally substituted on carbon by one or more R²¹;

R¹⁹ and R²¹ are independently selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, N-(C₁₋₆alkyl)amino, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, N-(C₁₋₆alkyl)sulphamoyl, N,N-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl or heterocyclyl; wherein R¹⁹ and R²¹ independently of each other may be optionally substituted on carbon by one or more R²³; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁴;

R²³ is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl, methylamino, ethylamino, dimethylamino, diethylamino, N-methyl-N-ethylamino, acetylamino, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-methyl-N-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N-methylsulphamoyl, N-ethylsulphamoyl, N,N-dimethylsulphamoyl, N,N-diethylsulphamoyl or N-methyl-N-ethylsulphamoyl; and

R²⁴ is selected from C₁₋₆alkyl, C₁₋₆alkanoyl, C₁₋₆alkylsulphonyl, C₁₋₆alkoxycarbonyl, carbamoyl, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

pyrimidinediamine;

5-chloro-N²-[1-(3-methyl-5-isoxazolyl)ethyl]-N⁴-(5-methyl-1H-pyrazol-3-yl)-2,4-pyrimidinediamine;
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;
5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or
5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

2. (original) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein A is a direct bond.

3. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein Ring C is phenyl, thienyl, pyridyl, thiazolyl.

4. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R¹ is selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkylS(O)_a wherein a is 0 or carbocyclyl; wherein R¹ may be optionally substituted on carbon by one or more R⁸; wherein R⁸ is selected from halo or carbocyclyl.

5. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R⁴ is hydrogen.

6. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein:

R² is selected from C₁₋₆alkyl; wherein R² may be optionally substituted on carbon by one or more R¹⁰;

R¹⁰ is selected from halo, hydroxy, carboxy, amino, C₁₋₆alkoxy, N,N-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, N-(C₁₋₆alkyl)carbamoyl, N,N-(C₁₋₆alkyl)₂carbamoyl or heterocyclyl; wherein R¹⁰ may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

R¹⁹ is selected from hydroxy or C₁₋₆alkoxy;

R²⁰ is selected from C₁₋₆alkyl.

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

7. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R^3 is selected from halo, nitro, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^3 may be optionally substituted on carbon by one or more R^{12} ; and R^{12} is selected from halo.

8. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R^5 is hydrogen or optionally substituted C_{1-6} alkyl; wherein said optional substituents are selected from one or more R^{14} ; and R^{14} is selected from hydroxy.

9. (currently amended) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein:

R^6 and R^7 are independently selected from hydrogen, halo, nitro, cyano, amino, C_{1-6} alkyl, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, N -(C_{1-6} alkyl)carbamoyl, C_{1-6} alkoxycarbonyl or heterocyclyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{16} ;

~~or R^6 and R^7 together with the pyrimidine bond to which they are attached form a 6 membered carbocyclic ring or a 5 or 6 membered heterocyclic ring wherein said ring is fused to the pyrimidine of formula (I); wherein the double bonds of the resulting bicyclic ring may be further delocalised across the whole of the bicyclic ring; and wherein said carbocyclic ring or heterocyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein if said heterocyclic ring contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{18} ;~~

R^{15} is selected from halo, hydroxy, amino, C_{1-6} alkoxy, N,N -(C_{1-6} alkyl)₂amino, carbocyclyl or heterocyclyl; wherein R^{15} may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;

R^{17} is selected from halo, C_{1-6} alkyl or C_{1-6} alkoxy; wherein R^{17} may be optionally substituted on carbon by one or more R^{18} ;

R^{16} is selected from C_{1-6} alkyl;

R^{18} is selected from C_{1-6} alkanoyl;

R^{19} is selected from halo, hydroxy, C_{1-6} alkoxy or heterocyclyl; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{24} ;

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

R^{20} is selected from C_{1-6} alkyl; and

R^{24} is selected from C_{1-6} alkyl.

10. (previously presented) A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein $n = 0$ or 1.

11. (previously presented) A compound of formula (II) according to claim 1 wherein:

A is a direct bond;

Ring C is phenyl, thienyl, pyridyl, thiazolyl;

R^1 is selected from hydrogen, methyl, ethyl, isopropyl, *t*-butyl, trifluoromethyl, cyclopropylmethyl, benzyl, methoxy, ethoxy, propoxy, isopropoxy, sec-butoxy, dimethylamino, methylthio or cyclopropyl;

R^2 is selected from methyl, ethyl, trifluoromethyl, hydroxymethyl, carboxymethyl, aminomethyl, methoxymethyl, morpholinomethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1-carboxyethyl, 2-dimethylaminoethyl, 2-diethylaminoethyl, acetamidomethyl, 2-[*N*-methyl-*N*-(2-methoxyethyl)amino]ethyl, 2-[*N*-methyl-*N*-(2-hydroxyethyl)amino]ethyl, 2-(*N*-methylcarbamoyl)ethyl, 2-[*N*-(2-hydroxyethyl)carbamoyl]ethyl, 2-(*N,N*-dimethylcarbamoyl)ethyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl or 2-(1-methylpiperazin-4-yl)ethyl, 1-methyl-2-hydroxyethyl;

R^3 is selected from fluoro, nitro, trifluoromethyl or methoxy;

R^4 is hydrogen;

R^5 is hydrogen, methyl or 2-hydroxyethyl;

R^6 and R^7 are independently selected from hydrogen, fluoro, chloro, bromo, nitro, cyano, amino, methyl, methylamino, ethylamino, propylamino, isopropylamino, dimethylamino, *N*-methyl-*N*-propylamino, *N*-ethylcarbamoyl, methoxycarbonyl, ethoxycarbonyl, butoxycarbonyl, morpholino, pyrrolidinyl or piperazinyl; wherein R^6 and R^7 independently of each other may be optionally substituted on carbon by one or more R^{15} ; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R^{16} ;

~~or R^6 and R^7 together with the pyrimidine to which they are attached form a bicyclic ring selected from quinoxalyl, thieno[3,2-*d*]pyrimidinyl, thieno[2,3-*d*]pyrimidinyl, 1*H*-pyrazolo[3,4-*d*]pyrimidinyl, thieno[3,4-*d*]pyrimidinyl, pyrido[2,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-pyrido[2,3-*d*]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-*d*]pyrimidinyl; and wherein said bicyclic ring may be optionally substituted on carbon by one or more R^{17} ; and wherein said 5,6,7,8-tetrahydro-pyrido[4,3-*d*]pyrimidinyl, 5,6,7,8-tetrahydro-~~

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

~~pyrido[2,3-d]pyrimidinyl or 5,6,7,8-tetrahydro-pyrido[3,4-d]pyrimidinyl may be optionally substituted on nitrogen by a group selected from R¹⁸;~~

R¹⁵ is selected from fluoro, hydroxy, amino, ethoxy, dimethylamino, phenyl, pyrrolidinyl, piperazinyl or morpholino; wherein R¹⁵ may be optionally substituted on carbon by one or more R¹⁸; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁰;

R¹⁶ is selected from methyl;

R¹⁷ is selected from fluoro, chloro, methyl, methoxy, ethoxy or propoxy; wherein R¹⁷ may be optionally substituted on carbon by one or more R¹⁸;

R¹⁸ is selected from acetyl;

R¹⁹ is selected from fluoro, hydroxy, methoxy, piperazinyl, pyrrolidinyl or morpholino; and wherein said piperazinyl may be optionally substituted on nitrogen by a group selected from R²⁴;

R²⁰ is selected from methyl;

R²⁴ is selected from methyl;

n = 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not:

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)propyl]-2,4-pyrimidinediamine;

5-chloro-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine;

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(3-pyridinyl)ethyl]-2,4-pyrimidinediamine; or

5-bromo-N⁴-(5-methyl-1H-pyrazol-3-yl)-N²-[1-(2-pyridinyl)ethyl]-2,4-pyrimidinediamine.

12. (currently amended) A compound of formula (I) selected from:

(2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoropyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;

5-bromo-N⁴-(3-cyclopropyl-1H-pyrazol-5-yl)-N²-[(1S)-1-(4-fluorophenyl)ethyl]pyrimidine-2,4-diamine;

(2R)-2-({5-chloro-4-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;

(2R)-2-({5-chloro-4-[(3-isopropoxy-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}amino)-2-(4-fluorophenyl)ethanol;


Application No.
Reply to Office Action of

10/395,807 Amendment Dated
December 31, 2008


June 1, 2009

(3S)-3-({5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrimidin-2-yl}amino)-3-(4-fluorophenyl)-N-methylpropanamide;
2-({5-chloro-2-[(1S)-1-(4-fluorophenyl)ethyl]amino}-6-[(5-isopropoxy-1H-pyrazol-3-yl)amino]pyrimidin-4-yl)amino)propane-1,3-diol;
2-[(5-chloro-6-[(3-cyclopropyl-1H-pyrazol-5-yl)amino]-2-[(1S)-1-(4-fluorophenyl)ethyl]amino]pyrimidin-4-yl)amino]propane-1,3-diol;
5-chloro-N⁴-(5-cyclopropyl-1H-pyrazol-3-yl)-N²-[(1S)-(4-fluoro-phenyl)-ethyl]-6-(4-methylpiperazin-1-yl)-pyrimidine-2,4-diamine;
~~(2R)-2-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-7-fluoroquinazolin-2-yl}amino)-2-(4-fluorophenyl)ethanol~~; and
2-[(5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]pyrimidin-4-yl)amino]propane-1,3-diol;
or a pharmaceutically acceptable salt thereof.

13. (previously presented) A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, which process comprises of *Process a)* reaction of a pyrimidine of formula (II):



wherein L is a displaceable group; with an pyrazole amine of formula (III):




Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009


or

Process b) reacting a pyrimidine of formula (IV):




(IV)

wherein L is a displaceable group; with a compound of formula (V):




(V)

Process c) reacting a compound of formula (VI):



(VI)

with a compound of formula (VII):



(VII)


Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

wherein X is an oxygen atom and q is 1; or X is a nitrogen atom and q is 2; and wherein each R^{20} independently represents a C_{1-6} alkyl group; or

Process d) reacting a compound of formula (VIII):



with hydrazine; or

and thereafter if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups;
- iii) forming a pharmaceutically acceptable salt.

14-17. (cancelled)

18. (previously presented) A method of inhibiting Trk activity comprising administering to a host in need of such treatment a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

19. (previously presented) A method for the treatment or prophylaxis of cancer comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

20. (previously presented) A method of producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1.

Application No.
Reply to Office Action of

10/595,807 Amendment Dated
December 31, 2008

June 1, 2009

21. (previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in claim 1, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

22-27. (cancelled)

28. (previously presented) The method according to claim 19 wherein said cancer is selected from oesophageal cancer, myeloma, hepatocellular, pancreatic, cervical cancer, ewings tumour, neuroblastoma, kaposi sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer - non small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, head and neck cancer, renal cancer, lymphoma, leukaemia, tumours of the central and peripheral nervous system, melanoma, fibrosarcoma and osteosarcoma.